Acellular Dermal Matrix vs Autologous Tarsus for Correction of Lower Eyelid Retraction

The goal of this clinical trial is to compare the effectiveness of two promising implants in treatment of lower eyelid retraction in 40 patients. This condition often resulting from injury, surgical complications, or thyroid eye disease. The main questions it aims to answer are: Which implant provides better long-term stability of the eyelid malposition? Does one implant minimize complications and improve patient outcomes more effectively than the other? This study will compare the use of donor sclera implants to a cellular dermal matrix to see if either offers superior results in terms of reducing graft shrinkage and improving eyelid positioning. Participants will: Undergo lower eyelid reconstruction surgery with one of the two implants. Be monitored for postoperative outcomes, including eyelid position, recurrence rates, and complications over a follow-up period 6 months.

NCT Number	NCT06926686
Lead Sponsor	Haukeland University Hospital
Conditions	Lower Eyelid Retraction
Enrollment	40 participants
Start Date	2025-01-01
Primary Completion	2030-01-01 (estimated)
Study Completion	2032-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-17